Blog

Clearing a way through the CRISPR patent jungle – Life Sciences Intellectual Property Review


Life Sciences Intellectual Property Review

Clearing a way through the CRISPR patent jungle
Life Sciences Intellectual Property Review
The revocation of the Broad Institute's patent EP2771468, reported and discussed here, marks the latest major development in a series of patent battles over the revolutionary and highly lucrative CRISPR/Cas 9 technology (and other gene-editing

2018-05-09 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.